Pharma: Other News To Note
Monday, October 1, 2012
Novo Nordisk A/S, of Bagsvaerd, Denmark, said the Japanese Ministry of Health, Labour and Welfare approved Tresiba (insulin degludec) to treat diabetes. The once-daily basal insulin studies showed a duration of action lasting beyond 42 hours in trials including 10,000 patients with Type I or Type II diabetes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.